Ray Therapeutics
Stories
-
Ray Therapeutics registers Phase 2/3 trial of RTx-015 in retinitis pigmentosa
The study plans to enroll 60 participants and is expected to start in October 2026, with primary completion projected for October 2028. It aims to evaluate the effectiveness and safety of a single intravitreal injection of the investigational gene therapy RTx-015 in participants with retinitis pigmentosa.